Drugs / StrataGraft
StrataGraft
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT04765202 | Oct 2021 → Jun 2024 | — | Stratatech, a Mallinckrodt Company | Terminated | Missed primary Stop: Business |
| Phase 1/2 | NCT00618839 | Jul 2006 → Apr 2008 | skin infection | Stratatech, a Mallinckrodt Company | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT05517902 | Apr 2023 → May 2024 | — | Stratatech, a Mallinckrodt Company | Completed | No outcome recorded |
| Phase 3 | NCT03005106 | May 2017 → Jul 2019 | — | Stratatech, a Mallinckrodt Company | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | StrataGraft | “Meshed autograft applied to the burn area and covered with StrataGraft.” NCT04765202 ↗ |
| Known as | StrataGraft skin substitute | “StrataGraft skin substitute exhibited a fully stratified epidermis with multilamellar lipid sheets and barrier function as well as robust human beta defensin-3 mRNA levels.” PMID 19276766 ↗ Mar 2009 |
| Known as | StrataGraft skin tissue | “StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid...” NCT00618839 ↗ |
| Known as | StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | “StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)” NCT04765202 ↗ |
| Modality | Other / unclassified | “StrataGraft is a pathogen-free human skin substitute that is ideal for the management of severe skin wounds before autografting.” PMID 19276766 ↗ Mar 2009 |